Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value ...

Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

U.S. pharmaceutical company Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for at least $1 billion U.S. The sale is part of Johnson & Johnson’s ongoing efforts ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched the CereGlide 92 catheter system for treating acute ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

VMP is an unpaid consultant for Siemens Healthinners Endovascular Robotics. JF reported compensation from Acandis, Cerenovus, MicroVention, Medtronic, Penumbra, Phenox, Roche, Stryker, Tonbridge and ...

Competing interests NK has been a consultant for Neurovasc. ST holds stock in Neurovasc and has been a consultant for Cerenovus, Medtronic, Neurovasc and Stryker. Patient consent Not required.

Johnson & Johnson is facing a critical test over its $10B proposal to end litigation alleging that its baby powder caused ovarian cancer, ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price ...

After hours: 7:59:27 pm GMT-5 ...